TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
FibroGen ( (FGEN) ) has provided an announcement.
On November 6, 2025, FibroGen, Inc. received a $6.4 million payment from AstraZeneca, fulfilling the first holdback condition of their share purchase agreement. This follows the August 29, 2025, sale of FibroGen’s China operations to AstraZeneca for approximately $220 million, impacting the company’s financials and strategic focus.
The most recent analyst rating on (FGEN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, persistent losses, and negative equity. While the earnings call provided some positive developments, such as the sale of FibroGen China and new clinical trials, these are overshadowed by the company’s ongoing financial struggles. Technical indicators and valuation metrics also reflect a challenging outlook, with no immediate signs of recovery.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
FibroGen, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of novel therapeutics to treat serious unmet medical needs.
Average Trading Volume: 42,346
Technical Sentiment Signal: Sell
Current Market Cap: $44.48M
For a thorough assessment of FGEN stock, go to TipRanks’ Stock Analysis page.